Drug availability adjustments in population-based studies of prescription opioid abuse

Alex Secora, James Phillip Trinidad, Rongmei Zhang, Rajdeep Gill, Gerald Dal Pan

Research output: Contribution to journalArticle

Abstract

Purpose: Population-based prescription opioid abuse studies in which one drug is compared to another, or drugs are compared across time, often account for the availability of those drugs in the community. The objective of this investigation is to assess consistency in the relative abuse ratios (RARs) across different approaches for adjusting for drug availability. Methods: For the years 2004 through 2010, RARs for each of four prescription opioids (hydrocodone, oxycodone, hydromorphone, and morphine) were calculated using negative binomial regression. Measures of abuse (outcome) were misuse/abuse-related emergency department visits obtained from the Drug Abuse Warning Network. Measures of drug availability (offsets) were drug utilization estimates obtained from IMS Health. Separate regression models were run using each of five measures of drug utilization: unique patients (URDD), prescriptions dispensed (RX), tablets dispensed (TD), kilograms (KGs) sold, and morphine-equivalents (MEs) of kilograms sold. These results were compared for consistency. Results: Aside from oxycodone-combination products, across molecules, RARs adjusted by RXs, TDs, and URDDs were generally similar to each other while RARs adjusted by KGs and MEs were different. For example, compared to hydrocodone, oxycodone had statistically significantly increased RARs of 3.6 (95%CI: 2.0–6.5), 3.5 (95%CI: 1.9–6.4), and 2.7 (95%CI: 1.5–5.0) when adjusted by URDDs, RXs, and TDs, respectively, but not when adjusted by KGs or MEs. Conclusions: Different drug utilization adjustment approaches may yield inconsistent RAR estimates in population-based prescription opioid abuse analyses. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

Original languageEnglish (US)
Pages (from-to)180-191
Number of pages12
JournalPharmacoepidemiology and Drug Safety
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Social Adjustment
Opioid Analgesics
Prescriptions
Oxycodone
Drug Utilization
Morphine
Hydrocodone
Pharmaceutical Preparations
Population
Hydromorphone
Public Sector
Tablets
Substance-Related Disorders
Hospital Emergency Service
Outcome Assessment (Health Care)
Health

Keywords

  • denominators
  • drug abuse
  • drug utilization
  • epidemiologic study
  • opioid
  • pharmacoepidemiology

ASJC Scopus subject areas

  • Epidemiology
  • Pharmacology (medical)

Cite this

Drug availability adjustments in population-based studies of prescription opioid abuse. / Secora, Alex; Trinidad, James Phillip; Zhang, Rongmei; Gill, Rajdeep; Dal Pan, Gerald.

In: Pharmacoepidemiology and Drug Safety, Vol. 26, No. 2, 01.02.2017, p. 180-191.

Research output: Contribution to journalArticle

Secora, Alex ; Trinidad, James Phillip ; Zhang, Rongmei ; Gill, Rajdeep ; Dal Pan, Gerald. / Drug availability adjustments in population-based studies of prescription opioid abuse. In: Pharmacoepidemiology and Drug Safety. 2017 ; Vol. 26, No. 2. pp. 180-191.
@article{dcceb985f2a54ee8aafbdd58d859ee12,
title = "Drug availability adjustments in population-based studies of prescription opioid abuse",
abstract = "Purpose: Population-based prescription opioid abuse studies in which one drug is compared to another, or drugs are compared across time, often account for the availability of those drugs in the community. The objective of this investigation is to assess consistency in the relative abuse ratios (RARs) across different approaches for adjusting for drug availability. Methods: For the years 2004 through 2010, RARs for each of four prescription opioids (hydrocodone, oxycodone, hydromorphone, and morphine) were calculated using negative binomial regression. Measures of abuse (outcome) were misuse/abuse-related emergency department visits obtained from the Drug Abuse Warning Network. Measures of drug availability (offsets) were drug utilization estimates obtained from IMS Health. Separate regression models were run using each of five measures of drug utilization: unique patients (URDD), prescriptions dispensed (RX), tablets dispensed (TD), kilograms (KGs) sold, and morphine-equivalents (MEs) of kilograms sold. These results were compared for consistency. Results: Aside from oxycodone-combination products, across molecules, RARs adjusted by RXs, TDs, and URDDs were generally similar to each other while RARs adjusted by KGs and MEs were different. For example, compared to hydrocodone, oxycodone had statistically significantly increased RARs of 3.6 (95{\%}CI: 2.0–6.5), 3.5 (95{\%}CI: 1.9–6.4), and 2.7 (95{\%}CI: 1.5–5.0) when adjusted by URDDs, RXs, and TDs, respectively, but not when adjusted by KGs or MEs. Conclusions: Different drug utilization adjustment approaches may yield inconsistent RAR estimates in population-based prescription opioid abuse analyses. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.",
keywords = "denominators, drug abuse, drug utilization, epidemiologic study, opioid, pharmacoepidemiology",
author = "Alex Secora and Trinidad, {James Phillip} and Rongmei Zhang and Rajdeep Gill and {Dal Pan}, Gerald",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/pds.4139",
language = "English (US)",
volume = "26",
pages = "180--191",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Drug availability adjustments in population-based studies of prescription opioid abuse

AU - Secora, Alex

AU - Trinidad, James Phillip

AU - Zhang, Rongmei

AU - Gill, Rajdeep

AU - Dal Pan, Gerald

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose: Population-based prescription opioid abuse studies in which one drug is compared to another, or drugs are compared across time, often account for the availability of those drugs in the community. The objective of this investigation is to assess consistency in the relative abuse ratios (RARs) across different approaches for adjusting for drug availability. Methods: For the years 2004 through 2010, RARs for each of four prescription opioids (hydrocodone, oxycodone, hydromorphone, and morphine) were calculated using negative binomial regression. Measures of abuse (outcome) were misuse/abuse-related emergency department visits obtained from the Drug Abuse Warning Network. Measures of drug availability (offsets) were drug utilization estimates obtained from IMS Health. Separate regression models were run using each of five measures of drug utilization: unique patients (URDD), prescriptions dispensed (RX), tablets dispensed (TD), kilograms (KGs) sold, and morphine-equivalents (MEs) of kilograms sold. These results were compared for consistency. Results: Aside from oxycodone-combination products, across molecules, RARs adjusted by RXs, TDs, and URDDs were generally similar to each other while RARs adjusted by KGs and MEs were different. For example, compared to hydrocodone, oxycodone had statistically significantly increased RARs of 3.6 (95%CI: 2.0–6.5), 3.5 (95%CI: 1.9–6.4), and 2.7 (95%CI: 1.5–5.0) when adjusted by URDDs, RXs, and TDs, respectively, but not when adjusted by KGs or MEs. Conclusions: Different drug utilization adjustment approaches may yield inconsistent RAR estimates in population-based prescription opioid abuse analyses. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

AB - Purpose: Population-based prescription opioid abuse studies in which one drug is compared to another, or drugs are compared across time, often account for the availability of those drugs in the community. The objective of this investigation is to assess consistency in the relative abuse ratios (RARs) across different approaches for adjusting for drug availability. Methods: For the years 2004 through 2010, RARs for each of four prescription opioids (hydrocodone, oxycodone, hydromorphone, and morphine) were calculated using negative binomial regression. Measures of abuse (outcome) were misuse/abuse-related emergency department visits obtained from the Drug Abuse Warning Network. Measures of drug availability (offsets) were drug utilization estimates obtained from IMS Health. Separate regression models were run using each of five measures of drug utilization: unique patients (URDD), prescriptions dispensed (RX), tablets dispensed (TD), kilograms (KGs) sold, and morphine-equivalents (MEs) of kilograms sold. These results were compared for consistency. Results: Aside from oxycodone-combination products, across molecules, RARs adjusted by RXs, TDs, and URDDs were generally similar to each other while RARs adjusted by KGs and MEs were different. For example, compared to hydrocodone, oxycodone had statistically significantly increased RARs of 3.6 (95%CI: 2.0–6.5), 3.5 (95%CI: 1.9–6.4), and 2.7 (95%CI: 1.5–5.0) when adjusted by URDDs, RXs, and TDs, respectively, but not when adjusted by KGs or MEs. Conclusions: Different drug utilization adjustment approaches may yield inconsistent RAR estimates in population-based prescription opioid abuse analyses. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

KW - denominators

KW - drug abuse

KW - drug utilization

KW - epidemiologic study

KW - opioid

KW - pharmacoepidemiology

UR - http://www.scopus.com/inward/record.url?scp=85007305988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007305988&partnerID=8YFLogxK

U2 - 10.1002/pds.4139

DO - 10.1002/pds.4139

M3 - Article

C2 - 28000295

AN - SCOPUS:85007305988

VL - 26

SP - 180

EP - 191

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 2

ER -